scholarly journals Approaches to the rational choice of type 5 phosphodiesterase inhibitors in patients presenting with cardiovascular and endocrine diseases

2010 ◽  
Vol 56 (6) ◽  
pp. 63-72
Author(s):  
V V Rafal'skiĭ ◽  
A N Baglikov
Keyword(s):  
Erectile Dysfunction ◽  
Side Effects ◽  
Rational Choice ◽  
Therapeutic Option ◽  
Phosphodiesterase Inhibitors ◽  
Pharmaceutical Products ◽  
Efficacy And Safety ◽  
Adverse Side Effects ◽  
Endocrine Diseases ◽  
Type 5 Phosphodiesterase Inhibitors

After the advent of four type 5 phosphodiesterase inhibitors (PDEI 5), viz. sildenafil, tadalafil, vardenafil, and udenafil, designed for the treatment of erectile dysfunction both physicians and patients found themselves faced with the problem of choosing an optimal therapeutic option. This paper contains comparative data on the efficacy and safety of different PDEI 5. The approaches to the rational choice of these preparations for the treatment of patients presenting with cardiovascular and endocrine diseases are discussed. Comparative controlled clinical studies failed to yield definitive information about advantages of one or another agent representing this group of pharmaceutical products. Nevertheless, the currently available data permit to draw the conclusion that the use of vardenafil and tadalafil ensures better compliance of patients with the prescribed therapy. Certain authors advocate the desirability of vardenafil application to the treatment of patients presenting with a background pathology. It is emphasized that all available PDEI 5 have a beneficial safety profile, with wardenafil being virtually free from adverse side effects.

Type 5 Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction and Cardiovascular Disease

2007 ◽  
Vol 15 (2) ◽  
pp. 76-86 ◽  
Author(s):  
Gautham Ravipati ◽  
John A. McClung ◽  
Wilbert S. Aronow ◽  
Stephen J. Peterson ◽  
William H. Frishman
Keyword(s):  
Cardiovascular Disease ◽  
Erectile Dysfunction ◽  
Phosphodiesterase Inhibitors ◽  
Type 5 Phosphodiesterase Inhibitors

Adverse Side Effects of 5α‐Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients

2011 ◽  
Vol 8 (3) ◽  
pp. 872-884 ◽  
Author(s):  
Abdulmaged M. Traish ◽  
John Hassani ◽  
Andre T. Guay ◽  
Michael Zitzmann ◽  
Michael L. Hansen
Keyword(s):  
Erectile Dysfunction ◽  
Side Effects ◽  
Adverse Side Effects ◽  
Reductase Inhibitors

scholarly journals Does high dose intravenous acetaminophen affect liver function for PDA closure in premature neonate?

2021 ◽  
Vol 47 (1) ◽  
Author(s):  
Reza Bahrami ◽  
Aida Ezzatabadi ◽  
Nima Mehdizadegan ◽  
Hamid Mohammadi ◽  
Hamid Amoozgar ◽  
...  
Keyword(s):  
Side Effects ◽  
Liver Function ◽  
Preterm Infants ◽  
Liver Enzymes ◽  
Premature Neonate ◽  
High Dose ◽  
Efficacy And Safety ◽  
Adverse Side Effects ◽  
Significant Difference ◽  
Intravenous Acetaminophen

Abstract Objectives The aim of this study was to collect consistent data on the efficacy and safety and evaluation hepatotoxicity of intravenous acetaminophen for the treatment of PDA in preterm infants. Methods This is an observational longitudinal prospective study on 46 preterm infants with PDA who treated with high dose of acetaminophen and evaluated with echocardiography and serum liver enzymes at Hafez and Zeinabiyeh hospitals from January 2016 to December 2019. Result Forty-six preterm infants with PDA treated with intravenous acetaminophen. Rate of closure of PDA was 82.6. There was no significant difference after treatment regarding AST, ALT, Albumin, total and direct bilirubin (P value > 0.05) and no adverse side effects were observed in association with intravenous acetaminophen. Conclusion High dose of acetaminophen is not more effective than that with standard doses although without hepatotoxic side effect for PDA closure.

scholarly journals Does high dose intravenous acetaminophen affect liver function for PDA closure in premature neonate?

2020 ◽  
Author(s):  
Reza Bahrami ◽  
Aida Ezzatabadi ◽  
Nima Mehdizadegan ◽  
Hamid Mohammadi ◽  
Hamid Amoozgar ◽  
...  
Keyword(s):  
Preterm Infants ◽  
Liver Enzymes ◽  
Therapeutic Option ◽  
Premature Neonate ◽  
P Value ◽  
High Dose ◽  
Efficacy And Safety ◽  
Adverse Side Effects ◽  
Significant Difference ◽  
Intravenous Acetaminophen

Abstract Objectives: The aim of this study was to collect consistent data on the efficacy and safety and evaluation hepatotoxicity of intravenous acetaminophen for the treatment of PDA in preterm infants.Methods: This is an observational longitudinal prospective study on 46 preterm infants with PDA who treated with high dose of acetaminophen and evaluated with echocardiography and serum liver enzymes at Hafez and Zeinabiyeh hospitals from January 2016 to December 2019.Result: Forty-six preterm infants with PDA treated with intravenous acetaminophen. Rate of closure of PDA was 82.6. There was no significant difference after treatment regarding AST, ALT, Albumin, total and direct bilirubin (P value >0.05) and no adverse side effects were observed in association with intravenous acetaminophen. Conclusion: High dose of acetaminophen is an effective and safe therapeutic option without hepatotoxic side effect for PDA closure.

scholarly journals Study of Efficacy and Safety of Ormeloxifene in the Management of Dysfunctional Menorrhagia

2014 ◽  
Vol 2 (1) ◽  
pp. 1-4
Author(s):  
Uma Gupta ◽  
Kumkum Shrivastava ◽  
Gunjan Katiyar ◽  
Ayesha Arif ◽  
Narendra Kumar Gupta
Keyword(s):  
Side Effects ◽  
Blood Loss ◽  
South Asian ◽  
Medical Management ◽  
Endometrial Thickness ◽  
Therapeutic Option ◽  
P Value ◽  
Efficacy And Safety ◽  
Loss Assessment ◽  
Treatment Side Effects

ABSTRACT Objective To assess the efficacy and safety of ormeloxifene in the medical management of dysfunctional menorrhagia. Methodology Fifty women with menorrhagia were recruited for the study. Ormeloxifene 60 mg twice a week for 3 months from first day of periods and once a week for next 3 months was given. Mean blood loss (MBL) was assessed using pictorial blood loss assessment chart (PBAC). Ultrasonography (USG) and blood hemoglobin levels were done as baseline and at 2, 4 and 6 months of treatment. Side-effects of the drug were recorded. Changes in PBAC scoring, endometrial thickness (ET) and hemoglobin levels (Hb) were analyzed by student's paired ‘t’ tests using SPSS 17.0 version. p value . 0.05 was taken as significant. Results The pretreatment PBAC score was 360, which reduced to 209.5 at 2 months, 88.7 at 4 months and 68.2 at 6 months of treatment, which was statistically significant (p-value . 0.001). The rise in hemoglobin and decrease in ET, in women on ormeloxifene was also statistically significant (p-value . 0.001). Conclusion Ormeloxifene is an effective and safe therapeutic option for the medical management of menorrhagia. How to cite this article Gupta U, Shrivastava K, Katiyar G, Arif A, Gupta NK. Study of Efficacy and Safety of Ormeloxifene in the Management of Dysfunctional Menorrhagia. J South Asian Feder Menopause Soc 2014;2(1):1-4.

scholarly journals Is high dose intravenous acetaminophen affect liver function in premature neonates with patent ductus arteriosus?

2020 ◽  
Author(s):  
Reza Bahrami ◽  
Aida Ezzatabadi ◽  
Nima Mehdizadegan ◽  
Hamid Mohammadi ◽  
Hamid Amoozgar ◽  
...  
Keyword(s):  
Preterm Infants ◽  
Liver Enzymes ◽  
Therapeutic Option ◽  
Ductus Arteriosus ◽  
P Value ◽  
High Dose ◽  
Efficacy And Safety ◽  
Adverse Side Effects ◽  
Significant Difference ◽  
Intravenous Acetaminophen

Abstract Objectives The aim of this study was to collect consistent data on the efficacy and safety and evaluation hepatotoxicity of intravenous acetaminophen for the treatment of PDA in preterm infants. Methods This is an observational longitudinal prospective study on 46 preterm infants with PDA who treated with high dose of acetaminophen and evaluated with echocardiography and serum liver enzymes at Hafez and Zeinabiyeh hospitals from January 2016 to December 2019. Result Forty-six preterm infants with PDA treated with intravenous acetaminophen. Rate of closure of PDA was 82.6. There was no significant difference after treatment regarding AST, ALT, Albumin, total and direct bilirubin (P value > 0.05) and no adverse side effects were observed in association with intravenous acetaminophen. Conclusion High dose of acetaminophen is an effective and safe therapeutic option without hepatotoxic side effect for PDA closure.

EFFICACY OF CARVEDILOL COMBINED WITH ENDOSCOPIC VARICEAL LIGATION IN THE PREVENTION OF RECURRENT VARICEAL BLEEDING IN PATIENTS OF CIRRHOSIS

2016 ◽  
pp. 23-30
Author(s):  
Van Huy Tran ◽  
Thi Ngoc Diep Bui
Keyword(s):  
Side Effects ◽  
Beta Blocker ◽  
Variceal Bleeding ◽  
Poor Prognosis ◽  
Oesophageal Varices ◽  
Endoscopic Variceal Ligation ◽  
Efficacy And Safety ◽  
Orthostatic Hypertension ◽  
Key Words Carvedilol ◽  
Very High

Background: The recurrent variceal bleeding is still very high with a very poor prognosis. The combination of a non-selective beta-blocker and endoscopic variceal ligation (EVL) is still a standard therapy for the prevention, but many patients showed no response to propranolol. Carvedilol is a new, non-selective beta-blocker having intrinsic alpha-blocker activity, but the data about the efficacy and safety of carvedilol is still very limited. This study is aimed at assessing the efficacy and safety of carvedilol combined with EVL in the prevention of recurrent variceal bleeding. Patients and methods: 33 patients having variceal bleeding were enrolled. All patients received carvedilol and were performed the EVL until variceal eradication. All the patients were followed after 9 months. Results: rate of variceal eradication of oesophageal varices was 87.88%; the recurrence rate of variceal bleeding was 12.12% after 9 months. The side effects of carvedilol were rare and not severe, including vertiges, headache, and orthostatic hypertension. Conclusion: Carvedilol combined with EVL appeared as a relatively safe and effective in the prevention of recurrent variceal bleeding in patients of cirrhosis. Key words: carvedilol, variceal bleeding, EVL

Sign in / Sign up

Export Citation Format

Share Document